Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling

Journal of Controlled Release

Volumn 61, Issue 1-2, 1999, Pages 93-106

  Harashima, Hideyoshi ^a   Iida, Shinya ^a   Urakami, Yumiko ^a   Tsuchihashi, Mari ^a   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Doxorubicin; Drug delivery system; Liposomes; Optimization; Simulation

Indexed keywords

DOXORUBICIN; LIPOSOME;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG RELEASE; ENCAPSULATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; SIMULATION;

ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; HUMANS; LIPOSOMES; MODELS, BIOLOGICAL;

EID: 0032839051     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00110-8     Document Type: Article

References (52)

1. Woodie M.C., Lasic D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta. 1113:1992;171-199.
2. Oku N. Long-circulating liposomes. Crit. Rev. Ther. Drug Carrier Syst. 11:1994;231-270.
3. Papahadjopoulos D., Alien T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.-D., Woodie M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA. 88:1991;11460-11464.
4. Huang S.K., Mayhew R., Gilani S., Lasic D.D., Martin F.J., Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 52:1992;6774-6781.
5. Vaage J., Mayhew E., Lasic D., Martin F. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int. J. Cancer. 51:1992;942-948.
6. Gabizon A.A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52:1992;891-896.
7. Vaage J., Donovan D., Mayhew E., Abra R., Huang A. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer. 72:1993;3671-3675.
8. Williams S.S., Alosco T.R., Mayhew E., Lasic D.D., Martin F.J., Bankert R.B. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res. 53:1993;3964-3967.
9. Fischi M.A., Krown S.E., O'Boyle K.P., Mitsuyasu R., Miles S., Wernz J.C., Volberding P.A., Kahn J., Groopman J.E., Feinberg J., Woody M. Weekly doxorubicin in the treatment of patients with aids-related Kaposi's sarcoma. J. Acquir. Immune Defic. Syndr. 6:1993;259-264.
10. Harrison M., Tomlinson D., Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 13:1995;914-920.
11. Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., Libson E., Muggia F.M., Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 13:1995;1777-1785.
12. Goebel F.-D., Goldstein D., Goos M., Jabionowski H., Stewart J.S. Efficacy and safety of stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Br. J. Cancer. 73:1996;989-994.
13. Sung C., Shockley Ty.R., Morrison P.F., Dvorak H.F., Yarmush M.L., Dedrick R.L. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res. 52:1992;377-384.
14. Baxter L.T., Zhu H., Mackensen D.G., Butler W.F., Jam R.K. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 55:1995;4511-4522.
15. Zhu H., Meider R.J., Baxter L.T., Jam R.K. Physiologically based kinetic model of effector cell biodistribution in mammals: Implications for adoptive immunotherapy. Cancer Res. 56:1996;3771-3781.
16. Ozawa S., Sugiyama Y., Mitsuhashi Y., Kobayashi T., Inaba M. Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother. Pharmacol. 21:1988;185-190.
17. Nakai D., Fuse E., Suzuki H., Inaba M., Sugiyama Y. Evaluation of the efficacy of targeting of antitumor drugs: Simulation analysis based on pharmacokinetic/pharmacodynamic consideration. J. Drug Target. 3:1996;443-453.
18. Uchiyama K., Nagayasu A., Yamagiwa Y., Nishida T., Harashima H., Kiwada H. Effects of the size and fluidity of liposomes on their accumulation in tumors: A presumption of their interaction with tumors. Int. J. Pharm. 121:1995;195-203.
19. Huang S.K., Lee K.-D., Hong K., Friend D.S., Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52:1992;5135-5143.
20. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jam R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Can. Res. 54:1994;3352-3356.
21. Evans W.E., Relling M.V. Clinical pharmacokinetics-pharmacodynamics of antitumor drugs. Clin. Pharmacokinetics. 16:1989;327-336.
22. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobiodyn. 4:1981;879-890.
23. Rahman A., Carmichael D., Harris M., Roh J.K. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res. 46:1986;2295-2299.
24. Yamaoka K., Nakagawa T.A. Nonlinear least squares program based on differential equations, MULTI(RUNGE), for microcomputers. J. Pharmacobiodyn. 6:1983;595-606.
25. Mayer L.D., Baily M.B., Cuilis P.R., Wilson S.L., Emerman J.T. Comparison of free and liposome-encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett. 53:1990;183-190.
26. Harashima H., Yamane C., Kume Y., Kiwada H. Kinetic analysis of AUC-dependent saturable clearance of liposomes: Mathematical description of AUC dependency. J. Pharmacokin. Biopharm. 21:1993;299-308.
27. Jam R.K. Transport of molecules in the tumor interstitium: A review. Cancer Res. 47:1987;3039-3051.
28. Jam R.K. Determinants of tumor blood flow: a review. Cancer Res. 48:1988;2641-2658.
29. Smith K.A., Hill S.A., Begg A.C., Denekamp J. Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumors. Br. J. Cancer. 57:1988;247-253.
30. Eskey C.J., Woimark N., McDowell C.L., Domach M.M., Jam R.K. Residence time distributions of various tracers in tumors: implications for drug delivery and blood flow measurement. J. Natl. Can. Inst. 86:1994;293-299.
31. Butler T.P., Grantham F.H., Guilino P.M. Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res. 35:1975;3084-3088.
32. Hon K., Zhang Qui-H., Saito S., Tanda S., Li Hao-C., Suzuki M. Microvascular mechanisms of change in tumor blood flow elicited by vasopressors. Jpn. J. Cancer Chemother. 21:1994;403-408.
33. Milano G., Cassuto-Viguier E., Fischei J.L., Formento P., Renee N., Frenay M., Thyss A., Namer M. Doxorubicin weekly low dose administration: in vitro cytotoxicity generated by the typical pharmacokinetic profile. Eur. J. Cancer. 28A:1992;1881-1885.
34. Horoqitz A.T., Barenhoiz Y., Gabizon A.A. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim. Biophys. Acta. 1109:1992;203-209.
35. Sawada Y., Harashima H., Hanano M., Sugiyama Y., Iga T. Prediction of the plasma concentration time courses of various drugs in humans based on data from rats. J. Pharmacobiol. Dyn. 8:1985;757-766.
36. Bjorkman S., Stanski D.R., Verotta D., Harashima H. Comparative tissue concentration profile of fentanyl and aifentanil in humans predicted from tissue/blood partition data obtained in rats. Anesthesiology. 72:1990;865-873.
37. Jusko W.J. Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J. Pharm. Sci. 60:1971;892-895.
38. Fuse E., Kobayashi T., Inaba M., Sugiyama Y. Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: integration of phamacokinetics with pharmacodynamics and toxicodynamics. Cancer Treat. Rev. 21:1995;133-157.
39. Sakakibara T., Chen F.-A., Kida H., Kunieda K., Cuenca R.E., Martin F.J., Bankert R.B. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res. 56:1996;3743-3746.
40. Eichhoitz-Wirth H. Dependence of the cytostatic effect of adriamycin on drug concentration and exposure time in vitro. Br. J. Cancer. 41:1980;886-891.
41. Saikawa A., Nomura T., Yamashita F., Takakura Y., Sezaki H., Hashida M. Pharmacokinetic analysis of drug disposition after intratumoral injection in a tissue-isolated tumor perfusion system. Pharm. Res. 13:1996;1438-1444.
42. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., Dewhirst M.W. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res. 53:1993;3765-3770.
43. Yuan F., Deilian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jam R.K. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res. 55:1995;3752-3756.
44. Horowitz A.T., Barenhoiz Y., Gabizon A.A. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim. Biophys. Acta. 1109:1992;203-209.
45. Ahmad I., Allen T.M. Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. Cancer Res. 52:1992;4817-4820.
46. Suzuki S., Watanabe S., Uno S., Tanaka M., Masuko T., Hashimoto Y. Biochim. Biophys. Acta. 1224:1994;445-453.
47. Forssen E.A., Male-Brune R., Adler-Moore J.P., Lee M.J.A., Schmidt P.G., Krasieva T.B., Shimizu S., Tromberg B.J. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res. 56:1996;2066-2075.
48. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 32:1973;302-314.
49. Bielack S.S., Erttman R., Winkler K., Landbeck G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur. J. Cancer Clin. Oncol. 25:1989;873-882.
50. van Hoesel Q.G.C.M., Steerenberg P.A., Crommelin D.J.A., van Dijk A., van Cort W., Klein S., Douze J.M.C., de Wildt D.J., Hilen F.C. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat. Cancer Res. 44:1984;3698-3705.
51. Gabizon A., Shiota R., Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl. Cancer Inst. 81:1989;1484-1488.
52. Harashima H., Midori Y., Ohshima S., Yachi K., Kikuchi H., Kiwada H. Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats (II). Biopharm. Drug Disposit. 14:1993;595-608.